Posted by Don Duncan
The US appellate court in Washington, DC, denied our appeal to reschedule cannabis under federal law today, agreeing with the Drug Enforcement Administration’s (DEA) position that “adequate and well-controlled studies” on the medical efficacy of medical cannabis do not exist. Americans for Safe Access (ASA) strongly disagrees with the court’s opinion. Our briefs referenced two hundred peer-reviewed scientific studies proving the medical value of cannabis.
The Obama Administration keeps changing the definition of medical efficacy. Politics have trumped medical science on this issue. ASA can point to a research approval process for medical cannabis, controlled by the National Institute on Drug Abuse (NIDA), which is unique, overly rigorous, and hinders meaningful therapeutic research. ASA argued in its appeal brief that the DEA has no “license to apply different criteria to marijuana than to other drugs, ignore critical scientific data, misrepresent social science research, or rely upon unsubstantiated assumptions, as the DEA has done in this case.”